FDA approves Kamada anti-rabies therapy Kedrab

Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said FDA approved Kedrab (human anti-rabies IgG therapy) for post-exposure prophylaxis of rabies infection when given immediately after contact with a suspected rabid animal. The anti-rabies IgG should be given concurrently with a full course of rabies vaccine. Kamada said Kedrab will launch in the U.S. early next year.

Kedrion S.p.A. (Barga, Italy) has exclusive rights from Kamada to commercialize Kedrab in the U.S. Kamada markets the product as KamRab outside of the U.S...